litlas
Log inCreate account

David Planchard

Active 2003–2025

197
Papers
49,340
Citations
86
h-index
181
i10-index

Citations

Citations per year for David Planchard1971: 1 citations1993: 2 citations1995: 1 citations2001: 1 citations2003: 2 citations2006: 1 citations2007: 1 citations2008: 4 citations2010: 3 citations2011: 8 citations2012: 12 citations2013: 26 citations2014: 46 citations2015: 151 citations2016: 274 citations2017: 396 citations2018: 549 citations2019: 2,086 citations2020: 2,863 citations2021: 3,013 citations2022: 2,346 citations2023: 2,003 citations2024: 3,307 citations2025: 1,853 citations2026: 54 citations1972–1992: no citations, so these years are not shown1994: no citations, so this year is not shown1996–2000: no citations, so these years are not shown2002: no citations, so this year is not shown2004–2005: no citations, so these years are not shown2009: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,715 citing papers, 20.8% of this breakdownChina: 3,367 citing papers, 14.9% of this breakdownItaly: 1,434 citing papers, 6.3% of this breakdownFrance: 1,288 citing papers, 5.7% of this breakdownJapan: 1,179 citing papers, 5.2% of this breakdownUnited Kingdom: 1,084 citing papers, 4.8% of this breakdownGermany: 930 citing papers, 4.1% of this breakdownSpain: 889 citing papers, 3.9% of this breakdownNetherlands: 660 citing papers, 2.9% of this breakdownCanada: 636 citing papers, 2.8% of this breakdownSouth Korea: 632 citing papers, 2.8% of this breakdownSwitzerland: 550 citing papers, 2.4% of this breakdown
0%20.8%Other 23.4%

Institutions

Fields

  • Medicine76.2%
  • Biochemistry, Genetics and Molecular Biology17.8%
  • Immunology and Microbiology3%
  • Engineering0.6%
  • Chemistry0.4%
  • Computer Science0.4%
  • Other1.6%

Topics

  • Cancer Immunotherapy and Biomarkers12.7%
  • Lung Cancer Treatments and Mutations12.3%
  • Lung Cancer Research Studies6.8%
  • Lung Cancer Diagnosis and Treatment5.1%
  • Cancer Genomics and Diagnostics3.6%
  • Immunotherapy and Immune Responses2.7%
  • Other56.8%

Coauthors

All papers

Open in search
  1. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

    Authors: Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam - New England Journal of Medicine 2017 cited by 5,269

  2. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    Authors: Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu - New England Journal of Medicine 2017 cited by 4,539

  3. Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

    Authors: Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria - New England Journal of Medicine 2019 cited by 2,816

  4. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    Authors: David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Özgüroğlu, Ki H. Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung C. Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia - Journal of Clinical Oncology 2022 cited by 1,295

  5. Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

    Authors: Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, Jose M. Pacheco, M. Pérol, Luis Paz‐Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Jänne - New England Journal of Medicine 2021 cited by 980

  6. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

    Authors: Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gérard Zalcman, S. Friard, Julien Mazières, Clarisse Audigier-Valette, Denis Moro‐Sibilot, François Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Mélodie Bonvalet, Arnaud Scherpereel, Hervé Pegliasco, Corentin Richard, François Ghiringhelli, Arielle Elkrief, Antoine Desîlets, Félix Blanc‐Durand, Fabio Cumbo, Aitor Blanco‐Míguez, Romain Boidot, Sandy Chevrier, Romain Daillère, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Éric Deutsch, Fabrice Barlési, David Planchard, Nicola Segata, Stéphanie Martinez, Laurence Zitvogel, Jean‐Charles Soria, Benjamin Besse - Nature Medicine 2022 cited by 642

  7. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Lizza Hendriks, Keith M. Kerr, Jessica Menis, Tony Mok, Ursula Nestle, Antonio Passaro, Solange Peters, David Planchard, Egbert F. Smit, Benjamin Solomon, Giulia Veronesi, Martin Reck - Annals of Oncology 2023 cited by 790

  8. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

    Authors: Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu - New England Journal of Medicine 2018 cited by 2,800

  9. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

    Authors: David Planchard, Pasi A. Jänne, Ying Cheng, James Chih‐Hsin Yang, Noriko Yanagitani, Sang‐We Kim, Shunichi Sugawara, Yan Yu, Yun Fan, Sarayut Lucien Geater, К. К. Лактионов, Chee Khoon Lee, Natalia Valdiviezo, Samreen Ahmed, Jean-Marc Maurel, Igor Andrašina, Jonathan W. Goldman, Dana Ghiorghiu, Yuri Rukazenkov, Alex Todd, Kunihiko Kobayashi - New England Journal of Medicine 2023 cited by 650

  10. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Lizza Hendriks, Keith M. Kerr, Jessica Menis, Tony Mok, Ursula Nestle, Antonio Passaro, Solange Peters, David Planchard, Egbert F. Smit, Benjamin Solomon, Giulia Veronesi, Martin Reck - Annals of Oncology 2023 cited by 580

  11. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: David Planchard, Sanjay Popat, Keith M. Kerr, Silvia Novello, Egbert F. Smit, Corinne Faivre‐Finn, Tony Mok, Martin Reck, Paul E. Van Schil, Matthew D. Hellmann, Solange Peters - Annals of Oncology 2018 cited by 2,299

  12. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

    Authors: Benjamin Besse, Mélinda Charrier, Valérie Lapierre, Éric Dansin, Olivier Lantz, David Planchard, Thierry Le Chevalier, Alain Livartoski, Fabrice Barlesi, Agnès Laplanche, Stéphanie Ploix, Nadège Vimond, Isabelle Péguillet, Clotilde Théry, Ludovic Lacroix, Inka Zoernig, Kavita M. Dhodapkar, Madhav V. Dhodapkar, Sophie Viaud, Jean‐Charles Soria, Katrin S. Reiners, Elke Pogge von Strandmann, Frédéric Vely, Sylvie Rusakiewicz, Alexander Eggermont, Jonathan M. Pitt, Laurence Zitvogel, Nathalie Chaput - OncoImmunology 2015 cited by 782

  13. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

    Authors: Kōichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, Elvire Pons‐Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong‐Wan Kim, Chih‐Hsi S. Kuo, James Chih‐Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne - Journal of Clinical Oncology 2023 cited by 299

  14. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    Authors: David Planchard, Egbert F. Smit, Harry J.M. Groen, Julien Mazières, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson - The Lancet Oncology 2017 cited by 1,367

  15. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

    Authors: Kathryn C. Arbour, Laura Mezquita, Niamh M. Long, Hira Rizvi, Édouard Auclin, Ai Ni, Gala Martínez-Bernal, Roberto Ferrara, W. Victoria Lai, Lizza Hendriks, Joshua K. Sabari, Caroline Caramella, Andrew J. Plodkowski, Darragh Halpenny, Jamie E. Chaft, David Planchard, Gregory J. Riely, Benjamin Besse, Matthew D. Hellmann - Journal of Clinical Oncology 2018 cited by 1,053

  16. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

    Authors: Laura Mezquita, Édouard Auclin, Roberto Ferrara, Mélinda Charrier, Jordi Remón, David Planchard, Santiago Ponce, Luis Paz Ares, Laura Leroy, Clarisse Audigier-Valette, Enriqueta Felip, Jorge Zerón-Medina, Pilar Garrido, Solenn Brosseau, Gérard Zalcman, Julien Mazières, Caroline Caramela, J. Lahmar, Julien Adam, Nathalie Chaput, Jean Charles Soria, Benjamin Besse - JAMA Oncology 2018 cited by 951

  17. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

    Authors: Lisa Derosa, Valerio Iebba, Carolina Alves Costa Silva, Gianmarco Piccinno, Guojun Wu, Leonardo Lordello, Bertrand Routy, Naisi Zhao, Cassandra Thélémaque, Roxanne Birebent, Federica Marmorino, Marine Fidelle, Meriem Messaoudene, Andrew Maltez Thomas, Gérard Zalcman, S. Friard, Julien Mazières, Clarisse Audigier-Valette, Denis Moro‐Sibilot, François Goldwasser, Arnaud Scherpereel, Hervé Pegliasco, François Ghiringhelli, Nicole Bouchard, Cissé Sow, Ines Darik, Silvia Zoppi, Pierre Ly, Anna Reni, Romain Daillère, Éric Deutsch, Karla A. Lee, Laura A. Bolte, Johannes R. Björk, Rinse K. Weersma, Fabrice Barlési, Lucas Padilha, Ana Finzel, Morten L. Isaksen, Bernard Escudier, Laurence Albigès, David Planchard, Fabrice André, Chiara Cremolini, Stéphanie Martinez, Benjamin Besse, Liping Zhao, Nicola Segata, Jérôme Wojcik, Guido Kroemer, Laurence Zitvogel - Cell 2024 cited by 181

  18. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Authors: Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim, David Planchard, Yuichiro Ohe, Suresh S. Ramalingam, Myung‐Ju Ahn, Sang-We Kim, Wu‐Chou Su, Leora Horn, Daniel Haggstrom, Enriqueta Felip, Joo-Hang Kim, Paul Frewer, Mireille Cantarini, Kathryn H. Brown, Paul A. Dickinson, Serban Ghiorghiu, Malcolm Ranson - New England Journal of Medicine 2015 cited by 2,111

  19. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

    Authors: David Planchard, Benjamin Besse, Harry J.M. Groen, Sayed M.S. Hashemi, Julien Mazières, Tae Min Kim, Élisabeth Quoix, Pierre‐Jean Souquet, Fabrice Barlési, Christina S. Baik, Liza C. Villaruz, Ronan J. Kelly, Shirong Zhang, Monique Tan, Eduard Gasal, Libero Santarpia, Bruce E. Johnson - Journal of Thoracic Oncology 2021 cited by 269

  20. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

    Authors: Egbert F. Smit, Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares, Jose M. Pacheco, Bob T. Li, David Planchard, Christina S. Baik, Yasushi Goto, Haruyasu Murakami, Andreas Saltos, Kaline Pereira, Ayumi Taguchi, Yingkai Cheng, Qi Yan, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne - The Lancet Oncology 2024 cited by 156

  21. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

    Authors: Mariona Riudavets, Ivana Sullivan, P. Abdayem, David Planchard - ESMO Open 2021 cited by 195

  22. Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

    Authors: Roberto Ferrara, Marie Naigeon, Édouard Auclin, Boris Duchemann, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Laura Mezquita, Matthieu Texier, Caroline Caramella, Lizza Hendriks, David Planchard, Jordi Remón, Sabina Sangaletti, Claudia Proto, Marina Chiara Garassino, Jean‐Charles Soria, Aurélien Marabelle, Anne-Laure Voisin, Siham Farhane, Benjamin Besse, Nathalie Chaput - Clinical Cancer Research 2020 cited by 155

  23. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

    Authors: David Planchard, Benjamin Besse, Harry J.M. Groen, Pierre-Jean Souquet, Élisabeth Quoix, Christina S. Baik, Fabrice Barlési, Tae Min Kim, Julien Mazières, Silvia Novello, James R. Rigas, Allison Upalawanna, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson - The Lancet Oncology 2016 cited by 878

  24. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

    Authors: Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín, Jan H.M. Schellens, Steven Kao, Wilson H. Miller, Jean‐Pierre Delord, Bo Gao, David Planchard, Maya Gottfried, Alona Zer, Shadia I. Jalal, Nicolas Penel, Janice M. Mehnert, Ignacio Matos, Jaafar Bennouna, Dong‐Wan Kim, Lei Xu, Suba Krishnan, Kevin Norwood, Patrick A. Ott - Journal of Thoracic Oncology 2019 cited by 438